Close Menu

Johns Hopkins

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

The FDA granted the assay's status based on its ability to detect both ovarian and pancreatic cancer in asymptomatic individuals over the age of 65.

In Science this week: genetic study of Homo floresiensis, approach for counting immune cells based on DNA signatures, and more.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The work is being funded with $26.5 million from the 21st Century Cures Cancer Moonshot Initiative.

An RNA test in development that confirms whether a patient has HCV within 40 minutes could enable diagnosis and prescribing treatment during a single office visit.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.

Metagenomics can help researchers and clinicians uncover sources of infectious disease and discern whether pathogens are resistant to antimicrobials.

Pages

The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.

Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.

NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.

In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.